La cadena de opciones muestra datos clave de las opciones de acciones de Actuate Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Actuate Therapeutics..

Actuate Therapeutics (NASDAQ:ACTU) Bolsa, Cadena de Opciones

Actuate Therapeutics

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics Inc

Liberty Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) has outperformed the market over the past 10 years by 2.72% on an annualized basis producing an average annual return of 13.77%. Currently, Liberty Media has a market capitalization of $24.37 billion. 
Buying $1000 In FWONK: If an investor had bought $1000 of FWONK stock 10 years ago, it would be worth $3,616.10 today based on a price of $97.68 for FWONK at the time of writing.
<h3>Liberty Media's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749504622_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

FWONK

Here's How Much $1000 Invested In Liberty Media 10 Years Ago Would Be Worth Today

General

SEZL

Sezzle Files Antitrust Lawsuit Against Shopify; Seeks Injunction To Stop Shopify's Anticompetitive Conduct; Reaffirms Fiscal 2025 Guidance

Lakeland Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $0.19 by 315.79 percent. This is a 207.89 percent decrease over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $46.75 million which missed the analyst consensus estimate of $48.85 million by 4.31 percent. This is a 28.74 percent increase over sales of $36.31 million the same period last year.

Earnings

Earnings Misses

LAKE

CORRECTION: Lakeland Industries Q1 EPS $(0.41) Misses $0.19 Estimate, Sales $46.75M Miss $48.85M Estimate

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 5 years by 21.26% on an annualized basis producing an average annual return of 35.8%. Currently, First Citizens BancShares has a market capitalization of $24.34 billion. 
Buying $100 In FCNCA: If an investor had bought $100 of FCNCA stock 5 years ago, it would be worth $475.83 today based on a price of $1831.72 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749503711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCNCA

Here's How Much $100 Invested In First Citizens BancShares 5 Years Ago Would Be Worth Today

Caseys General Stores Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) reported fourth-quarter financial results for fiscal 2025 after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/06/b45848759/caseys-announces-fourth-quarter-and-fiscal-year-results">of the report</a>.
<ul class="wp-block-list">
<li>Q4 Revenue: $3.99 billion, versus <a href="http://benzinga.com/quote/CASY/earnings">estimates</a> of $3.93 billion</li>
</ul>
<ul class="wp-block-list">
<li>Q4 EPS: $2.63, versus estimates of $2.01</li>
</ul>
Inside same-store sales were up&nbsp;1.7%&nbsp;year-over-year in the fourth quarter. Fuel same-store gallons were up&nbsp;0.1%&nbsp;compared to the prior year&#8217;s quarter. 
&#8220;Inside same-store sales outperformed the industry, up&nbsp;2.6%, or&nbsp;7.1%&nbsp;on a two-year stack basis, led by strong performance in hot sandwiches and bakery as well as alcoholic and non-alcoholic beverages. Our fuel team grew market share and produced a healthy margin, as fuel gross profit increased&nbsp;10.7%&nbsp;from the prior year,&#8221; said Darren Rebelez, president and CEO of Casey&#8217;s General Stores.
Casey&#8217;s announced a 14% increase to its quarterly dividend, bringing the dividend up to 57 cents per share. The company said it didn&#8217;t repurchase any stock during the period, and has $295 million remaining under its buyback. 
Casey&#8217;s ended the quarter with approximately $327 million&nbsp;in cash and cash equivalents on hand and approximately&nbsp;$900 million&nbsp;in undrawn borrowing capacity on existing lines of credit.
Outlook: Casey&#8217;s expects EBITDA to increase between 10% and 12% in fiscal 2026. The company anticipates a 2% to 5% increase in inside same-store sales. Same-store fuel gallons sold are expected to be approximately flat, plus or minus 1%. 
Casey&#8217;s noted that it expects to open at least 80 stores in fiscal 2026. 
CASY Price Action: <a href="http://benzinga.com/quote/CASY">Casey&#8217;s shares</a> were up 8.25% in after-hours, at $475.52 at the time of publication on Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45848752/hd-stock-sleeping-giant-offers-high-probability-trade">Options Corner: Sleeping Giant Home Depot Offers A High-Odds Play That No One&#8217;s Watching</a></li>
</ul>
Photo: Andriy Blokhin/Shutterstock.

Guidance

After-Hours Center

Movers

CASY

Casey's General Stores Stock Rises On Q4 Earnings Beat

<h3>Gainers</h3>
<ul>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 20.3% to $2.19 during Monday's after-market session. The company's market cap stands at $71.1 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares increased by 15.07% to $0.65. The market value of their outstanding shares is at $10.9 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares increased by 12.5% to $3.15. The company's market cap stands at $4.4 million. </li>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) shares increased by 8.09% to $1.87. The company's market cap stands at $21.4 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares moved upwards by 7.89% to $0.82. The company's market cap stands at $3.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares rose 6.69% to $0.08. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) stock fell 13.9% to $1.18 during Monday's after-market session. The market value of their outstanding shares is at $12.1 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares decreased by 12.68% to $4.41. The company's market cap stands at $259.2 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 9.1% to $0.45. The company's market cap stands at $26.5 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) stock fell 8.38% to $1.75. The company's market cap stands at $69.2 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock declined by 7.3% to $0.46. The company's market cap stands at $8.4 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares declined by 6.38% to $0.31. The company's market cap stands at $12.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ATHA

BCAB

CLGN

CTXR

INTS

KAPA

KLTO

NCNA

TELA

VERO

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) shares moved upwards by 8.4% to $475.78 during Monday's after-market session. The company's market cap stands at $17.3 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) stock moved upwards by 6.84% to $3.12. The company's market cap stands at $49.3 million. </li>
<li>Big Tree Cloud Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares increased by 5.22% to $1.41. The market value of their outstanding shares is at $80.4 million. </li>
<li>Borealis Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLS#NASDAQ">BRLS</a>) shares increased by 5.2% to $5.05. The market value of their outstanding shares is at $107.9 million. </li>
<li>CIMG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMG#NASDAQ">IMG</a>) shares moved upwards by 4.77% to $0.42. The market value of their outstanding shares is at $4.1 million. </li>
<li>Sadot Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) stock moved upwards by 4.27% to $1.22. The company's market cap stands at $7.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) shares declined by 14.0% to $23.8 during Monday's after-market session. The company's market cap stands at $424.5 million. As per the news, the Q2 earnings report came out today. </li>
<li>Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) shares fell 9.03% to $14.72. The market value of their outstanding shares is at $265.6 million. The company's, Q2 earnings came out today. </li>
<li>Ridgetech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDGT#NASDAQ">RDGT</a>) stock decreased by 5.27% to $1.08. The market value of their outstanding shares is at $6.3 million. </li>
<li>Upexi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares declined by 4.09% to $11.5. The company's market cap stands at $436.0 million. </li>
<li>Innovation Beverage Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) shares declined by 3.91% to $0.59. The market value of their outstanding shares is at $5.4 million. </li>
<li>Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) stock decreased by 3.71% to $1.82. The market value of their outstanding shares is at $164.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRFH

BRLS

CVGW

HAIN

LMNR

RDGT

SDOT

UPXI

12 Consumer Staples Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Skillsoft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKIL#NYSE">SKIL</a>) stock rose 15.2% to $21.0 during Monday's after-market session. The company's market cap stands at $178.1 million. As per the news, the Q1 earnings report came out today. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) stock increased by 7.54% to $0.57. The company's market cap stands at $5.4 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares moved upwards by 6.68% to $0.64. The market value of their outstanding shares is at $50.8 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares moved upwards by 6.3% to $0.45. The company's market cap stands at $7.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) shares increased by 5.85% to $0.28. The company's market cap stands at $15.7 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares increased by 5.76% to $0.09. The company's market cap stands at $12.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) shares declined by 6.7% to $0.55 during Monday's after-market session. The company's market cap stands at $7.3 million. </li>
<li>Loar Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) stock declined by 6.16% to $83.72. The company's market cap stands at $7.8 billion. </li>
<li>flyExclusive (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FLYX#AMEX">FLYX</a>) stock declined by 4.34% to $2.65. The market value of their outstanding shares is at $53.5 million. </li>
<li>Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) stock fell 4.24% to $1.13. The market value of their outstanding shares is at $22.0 million. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares fell 4.06% to $2.13. The market value of their outstanding shares is at $4.0 million. </li>
<li>Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) shares decreased by 4.01% to $34.75. The company's market cap stands at $1.7 billion. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FLYX

GFAI

LGCL

LNKS

LOAR

Nuveen Insured California Premium Fund Ii

SKIL

SOAR

XMTR

ZBAI

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares moved upwards by 148.3% to $2.11 during Monday's after-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>Digital Ally (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares moved upwards by 14.59% to $3.45. The market value of their outstanding shares is at $5.7 million. </li>
<li>One Stop Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>) shares rose 8.74% to $3.48. The market value of their outstanding shares is at $75.1 million. </li>
<li>Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) shares increased by 7.28% to $1.84. The company's market cap stands at $83.0 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock rose 5.45% to $1.16. The market value of their outstanding shares is at $11.9 million. </li>
<li>SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) stock increased by 4.97% to $10.55. The company's market cap stands at $1.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) shares declined by 19.6% to $1.35 during Monday's after-market session. The company's market cap stands at $185.5 million. </li>
<li>Schmid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHMD#NASDAQ">SHMD</a>) shares decreased by 10.75% to $2.4. The company's market cap stands at $103.3 million. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock fell 6.89% to $0.37. The company's market cap stands at $13.9 million. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) stock fell 6.64% to $2.11. The company's market cap stands at $26.4 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock decreased by 5.0% to $0.86. The market value of their outstanding shares is at $22.2 million. </li>
<li>AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) stock fell 5.0% to $0.76. The market value of their outstanding shares is at $14.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DGLY

GNSS

LDTC

LIDR

MRIN

ONDS

SAGT

SEMR

SHMD

SONM

12 Information Technology Stocks Moving In Monday's After-Market Session

With volatility dropping to multi-year lows, <a href="https://www.benzinga.com/etfs">volatility-linked ETFs</a> such as the ProShares VIX Short-Term Futures ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/VIXY#BATS">VIXY</a>), iPath Series B S&amp;P 500 VIX Short-Term Futures ETN (BATS:<a class="ticker" href="https://www.benzinga.com/stock/VXX#BATS">VXX</a>), and ProShares Ultra VIX Short-Term Futures ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/UVXY#BATS">UVXY</a>) are starting to appear increasingly appealing to traders who are gearing up for a market mood swing.
Read This: <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45846061/these-5-oil-etfs-can-ride-the-summer-demand-wave-amid-trade-talk-tailwinds">These 5 Oil ETFs Can Ride The Summer Demand Wave Amid Trade Talk Tailwinds</a>
These ETFs are created to appreciate as the CBOE Volatility Index (VIX) rises, particularly after a deep drop. Here&#8217;s their comparison:
ProShares VIX Short-Term Futures ETF
What it does: Tracks short-term VIX futures contracts.
Why it matters now: The VIX has plummeted more than 65% since peaking in early April, leaving room for big upside potential if market jitters return.
Caveat: VIXY is exposed to futures decay and is best employed for short-term tactical trades rather than long-term holdings.
iPath Series B S&amp;P 500 VIX Short-Term Futures ETN
What it does: Provides similar exposure to VIX futures, but in the form of a debt-backed ETN.
Appeal: Generally has cleaner tracking to the VIX index because of its structure.
Downside: Has the same roll costs as VIXY and involves issuer risk on Barclays.
ProShares Ultra VIX Short-Term Futures ETF
What it does: Offers 1.5x leveraged exposure to short-term VIX futures.
Why it&#8217;s compelling: UVXY can experience disproportionate gains if volatility snaps back, perfect for short durations of fear-driven trade.
High risk: Not for the faint of heart, daily resetting and futures decay can burn capital fast in dull or quiet markets.
Calm Now, Chaos Later?
The attractiveness of these ETFs is increasing as markets move into what looks like a volatility void. The <a href="https://www.benzinga.com/topic/vix">VIX just posted</a> its sharpest drop on record, as the S&amp;P 500 quietly <a href="https://www.benzinga.com/markets/equities/25/06/45840999/sp-500s-steady-climb-to-6000-just-killed-the-vix-what-this-volatility-crash-means-for-the-next-market-move">crossed the 6,000 mark</a>—brushing off rate anxiety and geopolitical tensions.
But this unsettling quiet has historically preceded chaos. Recall late 2017, when a sleepy VIX concealed risks responsible for the &#8220;Volmageddon&#8221; spike of 2018. And today, the same signs are simmering in the background:
Flattened skew in the options market suggests lower demand for protection against downward moves.
VVIX (VIX volatility) is still high, pointing to underlying hedging activity by institutions.
In short, the headline fear index might be sleeping, but shrewd money is creeping out to purchase crash insurance.
<h2 class="wp-block-heading">The Bottom Line</h2>
With the VIX trading at levels lower than their long-term averages, and complacency apparently baked into equity markets, the buying point on volatility-linked ETFs might be too good to pass up. VIXY, VXX, and UVXY present varying tools for those looking to position themselves for a possible volatility spike, whether it is macro shocks, earnings miss, or simply good old-fashioned mean reversion.
As the market hums along in a notably unblemished rhythm, it could be the moment to inject some static strategy, just in case the music does stop.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/06/45842911/exclusive-why-eric-lutton-says-sitting-in-cash-could-cost-you-big">EXCLUSIVE: Why Eric Lutton Says Sitting In Cash Could Cost You Big</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Broad U.S. Equity ETFs

Specialty ETFs

ETFs

UVXY

VIXY

Barclays Bank iPath S&P 500 VIX Short-Term Futures ETN

These 3 Volatility ETFs Look Poised For A Rebound As VIX Hits Record Lows

Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $58.0, a high estimate of $65.00, and a low estimate of $54.00. Experiencing a 3.73% decline, the current average is now lower than the previous average price target of $60.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1749502875_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Concentrix by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruplu Bhattacharya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ruplu Bhattacharya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Concentrix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Concentrix compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Concentrix's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Concentrix's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNXC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Concentrix analyst ratings.</a>
<h2>Discovering Concentrix: A Closer Look</h2>
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
<h3>Concentrix: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Concentrix's revenue growth over a period of 3M has faced challenges. As of 28 February, 2025, the company experienced a revenue decline of approximately -1.27%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Concentrix's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.82%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Concentrix's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Concentrix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.56%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.22.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CNXC

Analyst Expectations For Concentrix's Future

Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">13</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $14.98, a high estimate of $18.00, and a low estimate of $13.00. A 14.06% drop is evident in the current average compared to the previous average price target of $17.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1749502866_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Invesco by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.25</td>
<td>$15.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$14.50</td>
<td>$19.50</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Michael Carrier</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Invesco. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Invesco compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Invesco's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Invesco's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IVZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Invesco analyst ratings.</a>
<h2>All You Need to Know About Invesco</h2>
Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
<h3>Financial Insights: Invesco</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Invesco's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.65% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Invesco's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Invesco's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.61%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Invesco's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.62%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Invesco adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Invesco In The Eyes Of 14 Experts

In the latest quarter, 13 analysts provided ratings for nVent Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $70.23, a high estimate of $75.00, and a low estimate of $59.00. A decline of 6.47% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1749502853_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of nVent Electric by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Vladimir Bystricky</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$59.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$74.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Scott Graham</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
<tr>
<td>David Silver</td>
<td>CL King</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to nVent Electric. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of nVent Electric compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for nVent Electric's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into nVent Electric's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on nVent Electric analyst ratings.</a>
<h2>Discovering nVent Electric: A Closer Look</h2>
nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
<h3>nVent Electric: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: nVent Electric displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 10.54%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: nVent Electric's net margin excels beyond industry benchmarks, reaching 44.57%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): nVent Electric's ROE stands out, surpassing industry averages. With an impressive ROE of 10.53%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): nVent Electric's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.36% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: nVent Electric's debt-to-equity ratio is below the industry average. With a ratio of 0.52, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing nVent Electric: Insights From 13 Financial Analysts

Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.0, a high estimate of $20.00, and a low estimate of $12.00. This current average represents a 19.35% decrease from the previous average price target of $18.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1749502844_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Crescent Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$18.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Crescent Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Crescent Energy compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Crescent Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Crescent Energy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRGY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Crescent Energy analyst ratings.</a>
<h2>Get to Know Crescent Energy Better</h2>
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
<h3>Crescent Energy: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Crescent Energy's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 44.52%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Crescent Energy's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crescent Energy's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.07%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Crescent Energy's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Crescent Energy's debt-to-equity ratio surpasses industry norms, standing at 1.13. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGY

A Glimpse Into The Expert Outlook On Crescent Energy Through 6 Analysts

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $313.4, with a high estimate of $392.00 and a low estimate of $245.00. Highlighting a 10.15% decrease, the current average has fallen from the previous average price target of $348.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1749502830_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bio-Rad Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$245.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$310.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$392.00</td>
<td>$409.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$270.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bio-Rad Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bio-Rad Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bio-Rad Laboratories's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bio-Rad Laboratories analyst ratings.</a>
<h2>Discovering Bio-Rad Laboratories: A Closer Look</h2>
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
<h3>Bio-Rad Laboratories: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Bio-Rad Laboratories faced challenges, resulting in a decline of approximately -4.16% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Bio-Rad Laboratories's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.93% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Bio-Rad Laboratories's ROE excels beyond industry benchmarks, reaching 0.97%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Bio-Rad Laboratories's ROA stands out, surpassing industry averages. With an impressive ROA of 0.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Bio-Rad Laboratories's debt-to-equity ratio is below the industry average. With a ratio of 0.21, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Have This To Say About Bio-Rad Laboratories

Throughout the last three months, 4 analysts have evaluated Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $395.75, a high estimate of $417.00, and a low estimate of $352.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.31%. 
<img src="https://www.benzinga.com/files/images/story/2025/1749502818_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Hubbell among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$414.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$417.00</td>
<td>$352.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$352.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$400.00</td>
<td>$422.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Hubbell. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Hubbell compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Hubbell's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Hubbell's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUBB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hubbell analyst ratings.</a>
<h2>Unveiling the Story Behind Hubbell</h2>
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.
<h3>Breaking Down Hubbell's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Decline in Revenue: Over the 3M period, Hubbell faced challenges, resulting in a decline of approximately -2.42% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.41%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Hubbell's ROA excels beyond industry benchmarks, reaching 2.49%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.62.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HUBB

What 4 Analyst Ratings Have To Say About Hubbell

In the current session, Otis Worldwide Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) is trading at $95.32, after a 0.77% drop. Over the past month, the stock fell by 1.72%, and in the past year, by 1.22%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1749502819_0.png" alt="Past Year Chart" />

<h3>Evaluating Otis Worldwide P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Otis Worldwide has a lower P/E than the aggregate P/E of 27.95 of the Machinery industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749502819_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

OTIS

P/E Ratio Insights for Otis Worldwide

Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) has outperformed the market over the past 5 years by 25.96% on an annualized basis producing an average annual return of 40.49%. Currently, Tapestry has a market capitalization of $18.47 billion. 
Buying $100 In TPR: If an investor had bought $100 of TPR stock 5 years ago, it would be worth $561.33 today based on a price of $79.26 for TPR at the time of writing.
<h3>Tapestry's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749502813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Tapestry 5 Years Ago Would Be Worth Today

Offerings

NATR

Nature's Sunshine Products Files Prospectus Related To Offering And Resale Of 2.8M Shares Offered By Selling Stockholder

Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 15 years by 7.17% on an annualized basis producing an average annual return of 19.01%. Currently, Progressive has a market capitalization of $159.05 billion. 
Buying $100 In PGR: If an investor had bought $100 of PGR stock 15 years ago, it would be worth $1,395.63 today based on a price of $271.31 for PGR at the time of writing.
<h3>Progressive's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749501912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Progressive Stock In The Last 15 Years

Health Care

Press Releases

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Comments

Actuate Therapeutics

Actuate Therapeutics (ACTU) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL